Creative Medical Technology Holdings, Inc. (CELZ)
NASDAQ: CELZ · Real-Time Price · USD
2.175
-0.055 (-2.47%)
Apr 29, 2026, 9:47 AM EDT - Market open
CELZ Revenue
In the year 2025, Creative Medical Technology Holdings had annual revenue of $6.00K, down -45.45%. Creative Medical Technology Holdings had revenue of $3.00K in the quarter ending December 31, 2025.
Revenue (ttm)
$6.00K
Revenue Growth
-45.45%
P/S Ratio
1,373.93
Revenue / Employee
$1,500
Employees
4
Market Cap
8.04M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 6.00K | -5.00K | -45.45% |
| Dec 31, 2024 | 11.00K | 2.00K | 22.22% |
| Dec 31, 2023 | 9.00K | -79.60K | -89.84% |
| Dec 31, 2022 | 88.60K | 846.00 | 0.96% |
| Dec 31, 2021 | 87.75K | -76.75K | -46.65% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionCELZ News
- 1 day ago - Creative Medical Technology Holdings, Inc. Reports Breakthrough 93% Response Rate in Ultrasome™ Knee Osteoarthritis Program, Expanding CELZ-201 Platform into Scalable Cell-Free Regenerative Therapies - GlobeNewsWire
- 3 months ago - Creative Medical Technology Holdings Reaches Major Clinical Inflection Point with Positive Interim Data from ADAPT Trial and CELZ-201 (Olastrocel) in the Treatment of Chronic Lower Back Pain - GlobeNewsWire
- 4 months ago - Creative Medical Technology Holdings Receives Regulatory Approval for BioDefense Burn Pit Initiative - GlobeNewsWire
- 4 months ago - Creative Medical Technology Holdings, Inc. Completes Enrollment in FDA-Cleared ADAPT Trial for CELZ-201-Olastrocel, Marking Major Clinical Inflection Point - GlobeNewsWire
- 5 months ago - Creative Medical Technology Holdings Announces World Health Organization Approval of “olastrocel” as INN for Lead Allogeneic Cell Therapy CELZ-201 - GlobeNewsWire
- 6 months ago - Creative Medical Technology Holdings, Inc. Ignites Next-Gen Regenerative BioDefense Initiative for U.S. Veterans Exposed to Burn Pits - GlobeNewsWire
- 6 months ago - Creative Medical Technology Holdings Announces Agreements for Exercise of Warrants for $4.2 Million Gross Proceeds - GlobeNewsWire
- 6 months ago - Creative Medical Technology Holdings Issues Letter to Shareholders - GlobeNewsWire